Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/19/2023 | $8.00 | Overweight | Piper Sandler |
| 11/4/2022 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 3/8/2022 | $12.00 → $8.00 | Sector Perform | RBC Capital |
| 3/2/2022 | $8.00 → $6.00 | Market Perform | SVB Leerink |
| 2/9/2022 | $8.00 | Underweight → Neutral | JP Morgan |
| 1/10/2022 | $6.00 → $8.00 | Market Perform | SVB Leerink |
| 12/9/2021 | $8.00 → $9.00 | Sector Perform | RBC Capital |
| 11/19/2021 | $27.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
S-8 - Karyopharm Therapeutics Inc. (0001503802) (Filer)
10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass., Nov. 5,
NEWTON, Mass., Nov. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,500 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of October 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RS
-- Conference Call Scheduled for Tuesday, November 5, 2024, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2024 financial results on Tuesday, November 5, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, November 5, 2024, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (
NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer. "Dr. Su is a physician‐scientist and pharmaceutical industry leader who brings tremendous experience guiding products thro
DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs. Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinica
- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy - - As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr. Kauffman Will Transition Out of the Company on May 31, 2022 - - Dr. Shacham Will Continue her Engagement with the Company's Scientific Advisory Board and Serve in an Advisory Capacity - NEWTON, Mass., March 29, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Reshma Rangwala, MD, PhD, as the Company's Chief Medical Officer. Dr. Rangwala will join the Company in mid-April
HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price target from $8 to $7.
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 price target.
Piper Sandler initiated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $8.00
RBC Capital Mkts upgraded Karyopharm Therapeutics from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously
RBC Capital reiterated coverage of Karyopharm Therapeutics with a rating of Sector Perform and set a new price target of $8.00 from $12.00 previously
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass., Nov. 5,
-- Conference Call Scheduled for Tuesday, November 5, 2024, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2024 financial results on Tuesday, November 5, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, November 5, 2024, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (
Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) Remains a Co-primary Endpoint Promising Improvement in Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial Proactively Increasing Total Sample Size of the SENTRY Trial to Approximately 350 Patients to Further Increase the Statistical Powering; Expected Top-line Data Read-out Remains in 2H 2025 Company to Host a Conference Call Today at 8:00 a.m. ET Featuring Drs. Raajit Rampal and John Mascarenhas NEWTON, Mass., Oct. 31, 2024